Keynote address: perspectives on the use of interleukin-2 in cancer treatment.
Rosenberg
S A
SA
Surgery Branch, National Cancer Institute, Bethesda, Maryland 20592-0001, USA.
D002292:Carcinoma, Renal Cell / Q000628:therapy*; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000628:therapy*; D016246:Lymphocytes, Tumor-Infiltrating / Q000502:physiology; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014407:Tumor Cells, Cultured
D007376:Interleukin-2; D011994:Recombinant Proteins